Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

30 Sept 2019

Abstract excerpt

BACKGROUNDRV144 is the only preventive HIV vaccine regimen demonstrating efficacy in humans. Attempting to build upon RV144 immune responses, we conducted a phase 1, multicenter, randomized, double-blind trial to assess the safety and immunogenicity of regimens substituting the DNA-HIV-PT123 (DNA) vaccine for ALVAC-HIV in different sequences or combinations with AIDSVAX B/E (protein).METHODSOne hundred and four...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Herpesvirus Infections and Treatments
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31566579
DOI: 10.1172/jci128699

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trialPMID 31566579Read ↗

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and ESemantic proximity Read ↗

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteersSemantic proximity Read ↗

Translational research insights from completed HIV vaccine efficacy trials.Semantic proximity Read ↗

A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human VolunteersSemantic proximity Read ↗

HIV/AIDS Vaccines: 2018.Semantic proximity Read ↗

Germline-targeting chimpanzee SIV Envelopes induce V2-apex broadly neutralizing-like B cell precursors in a rhesus macaque infection modelSemantic proximity Read ↗

Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian AdultsSemantic proximity Read ↗

Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humansSemantic proximity Read ↗

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.Semantic proximity Read ↗

Broad Immunogenicity of a Multigene, Multiclade HIV‐1 DNA Vaccine Boosted with Heterologous HIV‐1 Recombinant Modified Vaccinia Virus AnkaraSemantic proximity Read ↗

Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIVSemantic proximity Read ↗

Vaccine Induction of Heterologous HIV-1 Neutralizing Antibody B Cell Lineages in HumansSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.